PHATHOM PHARMACEUTICALS, INC. Increase (Decrease) in Inventories
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Increase (Decrease) in Inventories of $3.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $3.96M, a 113.84% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was -$665.00K, a 105.39% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was -$2.00M, a 135.90% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$395.00K, a 194.50% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2025 was $11.78M, a 91.81% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2024 was $6.14M, a 34.95% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2023 was $9.44M.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.29M 10-Q · filed 2026-07-30 | $1.29M derived: sum of 3 quarters · filed 2026-07-30 | $894.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$665.00K 10-Q · filed 2026-04-30 | -$2.67M derived: sum of 2 quarters · filed 2026-04-30 | -$3.06M derived: sum of 3 quarters · filed 2026-04-30 | -$1.21M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.40M derived: sum of 2 quarters · filed 2026-02-26 | -$547.00K derived: sum of 3 quarters · filed 2026-07-30 | $11.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.46M derived: sum of 2 quarters · filed 2026-07-30 | $13.78M 10-Q · filed 2025-10-30 | $19.36M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $14.18M 10-Q · filed 2026-07-30 | $19.75M derived: sum of 3 quarters · filed 2026-07-30 | $20.17M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $12.33M 10-Q · filed 2026-04-30 | $17.90M derived: sum of 2 quarters · filed 2026-04-30 | $18.32M derived: sum of 3 quarters · filed 2026-04-30 | $18.05M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.99M derived: sum of 2 quarters · filed 2026-02-26 | $5.73M derived: sum of 3 quarters · filed 2026-02-26 | $6.14M 10-K · filed 2026-02-26 |
| 2024-09-30 | $418.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $150.00K derived: sum of 2 quarters · filed 2025-10-30 | $566.00K 10-Q · filed 2025-10-30 | $9.90M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$268.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $148.00K 10-Q · filed 2025-08-07 | $9.48M derived: sum of 3 quarters · filed 2025-08-07 | $9.59M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $416.00K 10-Q · filed 2025-05-01 | $9.75M derived: sum of 2 quarters · filed 2025-05-01 | $9.86M derived: sum of 3 quarters · filed 2025-05-01 | $9.86M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $9.44M derived: sum of 2 quarters · filed 2025-03-06 | $9.44M derived: sum of 3 quarters · filed 2025-03-06 | $9.44M 10-K · filed 2025-03-06 |
| 2023-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $111.00K derived: sum of 2 quarters · filed 2024-11-07 | $111.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-06-14 | |||
| 2022-12-31 | $0.00 10-K/A · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |